Rob Ortmann

Company: Aclaris

Job title: Vice President, Clinical Development

Seminars:

Utilising JAK Inhibitors in Identifying Areas of Unmet Needs that have the Potential to be Served 9:00 am

Exploring Aclaris’ current success of JAKi in Atopic Dermatitis Identifying the sub populations of patients within treated diseases that either are not well served and explore whether inhibition poses therapeutic possibilities Looking forward what are the next therapeutic opportunities with JAKRead more

day: Pre-Conference Workshop Day